TORONTO, July 13, 2018 /CNW/ - A proposed national class action has been commenced on behalf of all Canadians who purchased or ingested one or more of the valsartan medications which have been recalled. For more information go to http://valsartanclassaction.com.
In the proposed class action, the plaintiff alleges that the five defendant pharmaceutical companies who supplied contaminated valsartan to Canadians across the country, were negligent in their manufacturing of the drugs and in their failure to implement appropriate quality control testing when they received raw material from their supplier in China.
According to the Health Canada bulletin, NDMA is a potential human carcinogen which means that it could cause cancer with long-term exposure. According to Health Canada, the valsartan with the NDMA impurity was supplied by a Chinese manufacturer Zhejiang Huahai Pharmaceuticals. The defendants in the proposed class action are five pharmaceutical companies whose products appear on the Health Canada recall bulletin. The defendants are Teva Canada Limited, Sandoz Canada Inc., Pro Doc Limitee, Sanis Health Inc., and Sivem Pharmaceuticals ULC.
"It is horrifying that Canadians can never be sure what ingredients are going into their medication. We have no way of knowing where pharmaceutical companies are sourcing their ingredients, whether it is China or other countries around the world who may not have proper quality control measures in place. Maybe the time has come to identify the country of origin for drugs being sold to Canadians," said Ted Charney of Charney Lawyers PC.
Charney Lawyers is a leading class action firm. Mr. Charney has been counsel in major product liability class actions.
SOURCE Charney Lawyers
For further information: Ted Charney, Charney Lawyers PC, 416.964.7950 ext. 225, email@example.com